经皮穴位敷贴给药联合布地奈德雾化吸入治疗儿童支原体肺炎后咳嗽的临床疗效

Clinical efficacy of percutaneous acupoint application combined with inhalation of budesonide in the treatment of cough after mycoplasma pneumonia in children

目的探讨经皮穴位敷贴给药联合布地奈德雾化吸入治疗儿童支原体肺炎后咳嗽的临床疗效。方法 92例儿童支原体肺炎后咳嗽患儿,随机分为对照组与观察组,各46例。对照组患儿采用布地奈德雾化吸入治疗,观察组采用经皮穴位敷贴给药联合布地奈德雾化吸入治疗,比较两组临床疗效。结果两组治疗前咳嗽症状评分比较,差异无统计学意义(P>0.05);治疗后2、4、7 d两组患儿咳嗽症状均明显改善,观察组患儿咳嗽症状评分明显优于对照组,差异有统计学意义(P<0.05)。观察组患儿治疗总有效率为97.83%,明显优于对照组患儿的84.78%,差异有统计学意义(P<0.05)。结论对支原体肺炎后咳嗽患儿采用经皮穴位敷贴给药联合布地奈德雾化吸入治疗能够明显改善患儿咳嗽症状,且起效较快,缓解程度较好,值得在临床上推广应用。

Objective To investigate the clinical efficacy ofpercutaneous acupoint application combined with inhalation of budesonide in the treatment of cough after myeoplasma pneumonia in children. Methods A total of 92 children with cough after mycoplasma pneumonia were randomly divided into control group and observation group, with 46 cases in each group. The control group received inhalation of budesonide for treatment, and the observation group received percutaneous acupoint application combined with inhalation of budesonide for treatment. The clinical efficacy was compared in two groups. Results Both groups had no statistically significant difference in cough symptom score before treatment （P〉O.05）. After 2, 4 and 7 d of treatment, both groups had obviously improved cough symptoms, and the observation group had obviously better cough symptom score than the control group. Their difference had statistical significance （P〈0.05）. The observation group had obviously better total treatment effective rate as 97.83% than 84.78% in the control group, and their difference had statistical significance （P〈0.05）. Conclusion For children with cough after mycoplasma pneumonia, combination of percutaneous acupoint application and inhalation of budesonide can obviously improve the cough symptoms of children, and it has a quicker onset and a better degree of relief. So it is worthy of clinical promotion and application.